Skip to main content

Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy.

Publication ,  Journal Article
Agashe, S; Worrell, G; Britton, J; Noe, K; Ritaccio, A; Wirrell, EC; Nickels, KC; Cascino, GD; Burkholder, D
Published in: Neurol Clin Pract
April 2023

BACKGROUND AND OBJECTIVES: Cenobamate (CNB) is a United States Food and Drug Administration-approved antiseizure medication (ASM) for focal-onset seizures; however, its potential clinical effectiveness as a broad-spectrum ASM is not established. CNB has a proposed dual mechanism of action with preferential blockade of persistent sodium currents and positive allosteric modulation of the γ-aminobutyric acid-A (GABA-A) receptor. We evaluated the efficacy of CNB in drug refractory patients with genetic generalized epilepsies (GGE) or combined generalized and focal epilepsies (CGFE), including developmental and epileptic encephalopathies. METHODS: We performed a retrospective review and identified the following: cohort 1 (n = 4) with GGE, of which 2 patients had idiopathic generalized epilepsy, and cohort 2 with CGFE (n = 9), of which 4 patients had Lennox-Gastaut syndrome and 1 had Dravet syndrome. RESULTS: In cohort 1, all 3 patients with frequent generalized tonic-clonic seizures (GTCs) had a greater than 50% reduction in GTCs. In cohort 2, reduction in both generalized and focal-onset seizures was noted. In these groups together, the mean reduction of all seizure types was 58%, and ≥50% responder rate was 70% (SD = ±34.16, median = 50%). No worsening of generalized-onset seizures occurred in either cohort. Seventy-seven percent of patients experienced side effects, warranting a modification of treatment managed by slower titration, dose reduction of CNB, or discontinuing other ASMs. DISCUSSION: In our retrospective case series, CNB seems to be an effective ASM for patients with drug-resistant GGE and CGFE. The ongoing CNB trial assessing effectiveness for primary GTCs will provide more data on generalized-onset seizures. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that CNB in generalized epilepsy and combined generalized and focal epilepsy reduces seizure frequency.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neurol Clin Pract

DOI

ISSN

2163-0402

Publication Date

April 2023

Volume

13

Issue

2

Start / End Page

e200133

Location

United States

Related Subject Headings

  • 3209 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Agashe, S., Worrell, G., Britton, J., Noe, K., Ritaccio, A., Wirrell, E. C., … Burkholder, D. (2023). Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy. Neurol Clin Pract, 13(2), e200133. https://doi.org/10.1212/CPJ.0000000000200133
Agashe, Shruti, Gregory Worrell, Jeffrey Britton, Katherine Noe, Anthony Ritaccio, Elaine C. Wirrell, Katherine C. Nickels, Gregory D. Cascino, and David Burkholder. “Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy.Neurol Clin Pract 13, no. 2 (April 2023): e200133. https://doi.org/10.1212/CPJ.0000000000200133.
Agashe S, Worrell G, Britton J, Noe K, Ritaccio A, Wirrell EC, et al. Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy. Neurol Clin Pract. 2023 Apr;13(2):e200133.
Agashe, Shruti, et al. “Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy.Neurol Clin Pract, vol. 13, no. 2, Apr. 2023, p. e200133. Pubmed, doi:10.1212/CPJ.0000000000200133.
Agashe S, Worrell G, Britton J, Noe K, Ritaccio A, Wirrell EC, Nickels KC, Cascino GD, Burkholder D. Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy. Neurol Clin Pract. 2023 Apr;13(2):e200133.

Published In

Neurol Clin Pract

DOI

ISSN

2163-0402

Publication Date

April 2023

Volume

13

Issue

2

Start / End Page

e200133

Location

United States

Related Subject Headings

  • 3209 Neurosciences